| Gaucher Disease, Type 1
Cerezyme vs Zavesca
Side-by-side clinical, coverage, and cost comparison for gaucher disease, type 1.Deep comparison between: Cerezyme vs Zavesca with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsZavesca has a higher rate of injection site reactions vs Cerezyme based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Zavesca but not Cerezyme, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Cerezyme
Zavesca
At A Glance
IV infusion
3x/week to every 2 weeks
Glucocerebrosidase (enzyme replacement)
Oral
Three times daily
Glucosylceramide synthase inhibitor
Indications
- Gaucher Disease, Type 1
- Gaucher Disease, Type 3
- Gaucher Disease, Type 1
Dosing
Gaucher Disease, Type 1, Gaucher Disease, Type 3 2.5 units/kg three times a week to 60 units/kg once every two weeks, administered intravenously; titrate based on disease severity and therapeutic goals.
Gaucher Disease, Type 1 100 mg orally three times daily at regular intervals; may reduce to 100 mg once or twice daily for tremor or diarrhea; initiate at 100 mg twice daily for mild renal impairment (CrCl 50-70 mL/min/1.73 m2), 100 mg once daily for moderate impairment (CrCl 30-50 mL/min/1.73 m2); not recommended for severe renal impairment.
Contraindications
—
—
Adverse Reactions
Most common headache, dizziness, tachycardia, flushing, hypotension, hypertension, cough, dyspnea, abdominal pain, diarrhea, nausea, vomiting, pruritus, rash, urticaria, back pain, chest discomfort, chills, fatigue, infusion-site burning, infusion-site discomfort, infusion-site swelling, pyrexia
Serious anaphylaxis, hypersensitivity reactions, pneumonia, pulmonary hypertension, angioedema, cyanosis
Most common (>=5%) Diarrhea, flatulence, abdominal pain, nausea, weight decrease, headache, tremor, thrombocytopenia
Serious Peripheral neuropathy
Pharmacology
Imiglucerase is a recombinant analogue of human beta-glucocerebrosidase that catalyzes the hydrolysis of glucocerebroside to glucose and ceramide; mannose-terminated oligosaccharide chains mediate binding to and uptake into macrophages and other target cells, replacing deficient enzyme activity in Gaucher disease.
Miglustat is a competitive and reversible inhibitor of glucosylceramide synthase, reducing glycosphingolipid biosynthesis so that the residual activity of deficient glucocerebrosidase can more effectively degrade glucosylceramide substrate (substrate reduction therapy).
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Cerezyme
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (0/12)
Zavesca
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Cerezyme
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Zavesca
- Covered on 4 commercial plans
- PA (2/8) · Step Therapy (0/8) · Qty limit (0/8)
Humana
Cerezyme
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (2/3) · Qty limit (0/3)
Zavesca
- Covered on 0 commercial plans
- PA (2/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
Cost estimate not availableAccessia Health: Gaucher Disease - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAccessia Health: Gaucher Disease - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
CerezymeView full Cerezyme profile
ZavescaView full Zavesca profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.